[1] SMYTH MJ, GODFREY DI, TRAPANI JA.A fresh look at tumor immunosurveillance and immunotherapy[J].Nat Immunol, 2001, 2(4):293. doi: 10.1038/86297
[2] ATKINS MB, SZNO ML.Cancer immunotherapy:past progress and future directions[J].Semin Oncol, 2015, 42(4):518. doi: 10.1053/j.seminoncol.2015.05.001
[3] PAGE DB, POSTOW MA, CALLAHAN MK, et al.Immunemodulation in cancer with antibodies[J].Annu Rev Med, 2013, 65(1):185.
[4] KERSHAW MH, WESTWOOD JA, SLANEY CY, et al.Clinical application of genetically modified T cells in cancer therapy[J].Clin Transl Immunol, 2014, 3:16. doi: 10.1038/cti.2014.7
[5] ROSENBERG SA.Raising the bar:the curative potential of human cancerimmunotherapy[J].Sci Transl Med, 2012, 127(4):127ps8.
[6] ROBERT C, SCHACHTER J, LONG GV, et al.Pembrolizumab versus ipilimumab in advanced melanoma[J].N Engl J Med, 2015, 372(26):2521. doi: 10.1056/NEJMoa1503093
[7] ISHIDA Y, AGATA Y, SHIBAHARA K, et al.Induced expression of PD-1, a novel member of the immunolobin gene superfamily, upon programmed cell-death[J].Embv J, 1992, 11(11):3887. doi: 10.1002/embj.1992.11.issue-11
[8] DONG H, ZHU G, TAMADA K, et al.B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J].Nat Med, 1999, 5(12):1365. doi: 10.1038/70932
[9] FREEMAN GJ, LONG AJ IWAI Y, et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J].J Exp Med, 2000, 192(7):1027. doi: 10.1084/jem.192.7.1027
[10] SUN H, SUN C, XIAO W.Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokinestimulations[J].Cytokine, 2014, 65(1):33. doi: 10.1016/j.cyto.2013.09.016
[11] IRAOLAGOITIA XL, SPALLANZANI RG, TORRES NI, et al.NK cells restrain spontaneous antitumor CD8+ Tcell priming through PD-1/PD-L1 interactions with dendritic cells[J].J Immunol, 2016, 197(3):953. doi: 10.4049/jimmunol.1502291
[12] LATCHMAN Y WOOD CR, CHERNOVA T, et al.PD-L2 is a second ligand for PD-1and inhibits Tcell activation[J].Nat Immunol, 2001, 2(3):261. doi: 10.1038/85330
[13] STEMPIN CC, MOTRAN CC, AOKI MP, et al.PD-L2 negatively regulates Th1-mediated immunopathology during Fasciola hepaticainfection[J].Oncotarget, 2016, 7(47):77721.
[14] CHEMNITZ JM, PARRY RV, NICHOLS KE, et al.SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human Tcell stimulation, but only receptor ligation prevents Tcell activation[J].J Immunol, 2004, 173(2):945. doi: 10.4049/jimmunol.173.2.945
[15] LASTWIKA KJ, WILSON W, LI QK, et al, Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer Res[J].Oncogene, 2016, 72(2):227.
[16] KOH YW, JEON YK, YOON DH, et al.Programmed death 1 expression the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma[J].Tumour Biol, 2016, 37(6):7507. doi: 10.1007/s13277-015-4622-5
[17] TOPALIAN SL, DRAKE CG, PARDOLL DM.Immune checkpoint blockade:a common denominator approach to cancer therapy[J].Cancer Cell, 2015, 27(4):450. doi: 10.1016/j.ccell.2015.03.001
[18] PARSA AT, WALDRON JS, PANNER A, et al.Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma[J].Nat Med, 2007, 13(1):84. doi: 10.1038/nm1517
[19] 景楚瑜.抗PD-1/PD-L1治疗在肿瘤治疗中的研究进展[J].复旦学报, 2016, 43(6):1672.
[20] ZIPPELIUS A, SCHREINER J, HERZIG P, et al.Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment[J].Cancer Immunol Res, 2015, 3(3):236. doi: 10.1158/2326-6066.CIR-14-0226
[21] MURPHY K, TRAVERS P, WALPORT M.Janeway's immunobiology[M].8th.Beijing:Garland Science, 2011:685.
[22] 张力.非小细胞肺癌的免疫治疗新进展[J].医学与哲学, 2015, 36(4):13.
[23] 赖胜蓝, 王江涛.非小细胞肺癌抗PD-1/PD-L1治疗研究进展[J].中国继续医学教育, 2017, 9(1):145. doi: 10.3969/j.issn.1674-9308.2017.01.085
[24] DONG H, STROME SE, SALOMAO DR, et al.Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion[J].Nat Med, 2002, 8(8):793. doi: 10.1038/nm730
[25] 潘佳佳, 贾晓青, 黄岗, 等.PD-1/PD-Ls信号通路及其抗体在肿瘤治疗中的应用[J].中国药科大学学报, 2016, 47(1):9.
[26] 徐泱, 喻敏成.抗PD-1/PD-L1抗体在肿瘤治疗中的研究[J].外科与理论实践, 2018, 23(3):227.
[27] TROJAN J, SARRAZIN C.Complete response of hepatocellular carcinoma in a patient with end-stage liver disease treated with nivolumab:whishful thinking or possible?[J].Am J Gastroenterol, 2016, 111(8):1208.
[28] 高蓓蓓, 李代强.PD-1/PD-L1在非小细胞瘤肺癌中的研究进展及展望[J].临床与病理杂志, 2015, 35(6):1189.
[29] HUI R, GARON EB, GOLDMAN JW, et al.Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer:a phase 1 trial[J].Ann Oncol, 2017, 28(4):874. doi: 10.1093/annonc/mdx008
[30] GOLDBERG SB, GETTINGER SN, MAHAJAN A, et al.Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases:early analysis of a non-randomised, open-label, phase 2 trial[J].Lancet Oncol, 2016, 17(7):976. doi: 10.1016/S1470-2045(16)30053-5
[31] ATKINS MB, KUDCHADKAR RR, SZNOL M, et al.Phase 2, multi center, safety and efficacy study of pidilizumab in patients with metastatic melanoma[C].ASCO Annual Meeting Proceedings, 2014, 32(15): 9001.
[32] WESTIN JR, CHU F, ZHANG M, et al.Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma:a single group, open label, phase 2 trial[J].Lancet Oncol, 2014, 15(1):69. doi: 10.1016/S1470-2045(13)70551-5
[33] KAYLA FAITH MOORE, PHARM D.Use of Atezolizumabfor bladder cancer and NSCLC[J].Med Lett Drugs Ther, 2017, 1515(59):40.
[34] KAUFMAN HL, RUSSELL J, HAMID O, et al.Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma:a multicentre, single-group, open-label, phase 2 trial[J].Lancet Oncol, 2016, 17(10):1374. doi: 10.1016/S1470-2045(16)30364-3
[35] POWLES T, EDER JP, FINE GD, et al.MPDL3280A (anti-PD-L1)treatment leads to clinical activity in metastatic bladder cancer[J].Nature, 2014, 7528(515):558.
[36] EMENS LA, BRAITEH FS, CASSIER P, et al.Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer[J].Cancer Res, 2015, 75(15 Suppl):2859.
[37] SEGAL NH, ANTONIA SJ, BRAHMER JR, et al.Preliminary data from amulti-arm expansion study of MEDI4736, an anti-PD-L1 antibody[J].J Clin Oncol, 2014, 32(15 Suppl):134136.
[38] BRAHMER JR, TYKODI SS, CHOW LQ, et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J].N Engl J Med, 2012, 366(26):2455. doi: 10.1056/NEJMoa1200694
[39] DISIS ML, PATEL MR, PANT S, et al.Avelumab(MSB0010718C), an anti-PD-L1 antibodyin patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-labelexpansion trial[C].ASCO Annual Meeting Proceedings, 2015, 33(15 Suppl): 5509.
[40] POSTOW MA, CALLAHAN MK, WOLCHOK JD.Immune checkpoint blockade in cancer therapy[J].J Clin Oncol, 2015, 33(17):1974. doi: 10.1200/JCO.2014.59.4358
[41] FRIEDMAN CF, PROVERBS-SINGH TA, POSTOW MA.Treatment of tne immune-related adverse effects of immune checkpoint inhibitors:a review[J].JAMA Oncol, 2016, 2(10):1346. doi: 10.1001/jamaoncol.2016.1051
[42] CALABRESE L, MARIETTE X.The evolving role of the rheumatologist in the management of immune-related adverse events(irAEs) caused by cancer immunotherapy[J].Ann Rheum Dis 2018, 77(2):162. doi: 10.1136/annrheumdis-2017-212061
[43] 喻敏成, 胡博, 付佩尧, 等.抗PD-1/PD-L1抗体临床治疗不良反应研究进展[J].中国临床医学, 2018, 25(4):625.